Open Orphan PLC (LON:ORPH) has drawn investors’ attention to an article in ‘Drug Discovery Today’ written by a director at its hVIVO subsidiary.
The print and online trade magazine with an emphasis on the science that underpins drug discovery and development has published an editorial entitled “Modelling the World – can deliberately infecting healthy volunteers really tell us much about what happens outside the clinic during an epidemic or pandemic?”
The article was written by Adrian Wildfire, director of Scientific and Business Strategy at hVIVO, which is part of Open Orphan. Wildfire is a specialist in the fields of virology, medical microbiology and parasitology.
The article explores what can be learned from using the method of human challenge trials to support vaccine development, and focuses on the role hVIVO plays in this, in particular in relation to coronavirus (COVID-19). hVIVO has a long history of successfully delivering human challenge studies at its state-of-the-art quarantine facility in East London.